Barclays’s 89bio ETNB Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q4 | – | Sell |
-527,069
| Closed | -$7.75M | – | 5366 |
|
|
2025
Q3 | $7.75M | Buy |
527,069
+38,358
| +8% | +$391K | ﹤0.01% | 1862 |
|
|
2025
Q2 | $4.8M | Sell |
488,711
-338,149
| -41% | -$2.8M | ﹤0.01% | 2170 |
|
|
2025
Q1 | $6.01M | Buy |
826,860
+186,886
| +29% | +$1.63M | ﹤0.01% | 1766 |
|
|
2024
Q4 | $5M | Buy |
639,974
+425,206
| +198% | +$3.5M | ﹤0.01% | 2169 |
|
|
2024
Q3 | $1.59M | Buy |
214,768
+149,479
| +229% | +$1.26M | ﹤0.01% | 3039 |
|
|
2024
Q2 | $523K | Sell |
65,289
-288,799
| -82% | -$2.58M | ﹤0.01% | 3020 |
|
|
2024
Q1 | $4.12M | Sell |
354,088
-189,464
| -35% | -$2.1M | ﹤0.01% | 1995 |
|
|
2023
Q4 | $6.07M | Sell |
543,552
-80,813
| -13% | -$743K | ﹤0.01% | 1930 |
|
|
2023
Q3 | $9.64M | Buy |
624,365
+428,297
| +218% | +$7.19M | 0.01% | 1012 |
|
|
2023
Q2 | $3.72M | Buy |
196,068
+43,192
| +28% | +$758K | ﹤0.01% | 1521 |
|
|
2023
Q1 | $2.33M | Sell |
152,876
-256,269
| -63% | -$3.34M | ﹤0.01% | 2078 |
|
|
2022
Q4 | $5.21M | Buy |
409,145
+20,163
| +5% | +$181K | ﹤0.01% | 1586 |
|
|
2022
Q3 | $2.25M | Buy |
388,982
+364,518
| +1,490% | +$1.6M | ﹤0.01% | 1668 |
|
|
2022
Q2 | $79K | Buy |
24,464
+2,920
| +14% | +$8.81K | ﹤0.01% | 3863 |
|
|
2022
Q1 | $81K | Buy |
+21,544
| New | +$139K | ﹤0.01% | 3884 |
|
Other funds holding ETNB
Barclays's ETNB Position: Q4 2025 in Review
Barclays sold out of 89bio (ETNB) in Q4 2025, closing a stake of 527,069 shares — an estimated $7.75M sold.
Barclays first reported a position in ETNB in Q1 2022 and held it in 15 quarters. The position peaked at $9.64M in Q3 2023. 2 funds tracked by Wall St. Rank hold ETNB as of Q4 2025.
- Barclays reported no remaining 89bio position as of Q4 2025 after selling out during the quarter.
- Barclays sold 527,069 89bio shares in Q4 2025, an estimated $7.75M.
- Barclays first reported a position in 89bio in Q1 2022 and held it in 15 quarters.
- Barclays's 89bio position peaked at $9.64M in Q3 2023.
- 2 funds tracked by Wall St. Rank held 89bio as of Q4 2025.
Based on Barclays's 13F filing for Q4 2025, filed 13 Feb 2026.